Certain cases of cancer may respond well to conservative analgesic therapy initially but eventually require multimodal analgesia.

About 45% to 65% of hypercalcemic dogs and 10% to 30% of hypercalcemic cats have underlying neoplasia.

Mammary tumors are the third most common feline cancer, 1-3 accounting for 10.3% to 12% of all diagnosed tumors.

Transitional cell carcinoma of the urinary bladder is by far the most common neoplasm of the urinary system in dogs.

Cancer remains one of the most common serious ailments of aging pets. However, better diagnostic capabilities and improved therapeutic options now often translate into enhanced quality of life and longer survival.

Metastatic, disseminated, and locally infiltrative cancers, including metastatic carcinoma, melanoma, lymphoma, hemangiosarcoma, and histiocytic sarcoma, can often affect the hepatic parenchyma.

Recent publications, ongoing prospective studies, and better knowledge of the available therapeutic options should provide the necessary framework for appropriate pain management in cancer-bearing pets.

Pain negatively affects quality of life as well as many important physiological functions, so controlling it in all patients should be a top priority.

Because you will likely encounter canine cutaneous mast cell tumors in your practice, this review article focuses on summarizing the therapeutic options available for treating canine mast cell tumors. With a better understanding of available treatment regimens, you will be able to educate and guide pet owners regarding the treatment options that may best suit their dogs.